In this Review, the authors discuss guideline-directed medical therapy for diabetic kidney disease and the evolving clinical evidence for next-generation therapies, including incretin-based therapies, endothelin receptor antagonists, aldosterone synthase inhibitors, soluble guanylate cyclase agonists and anti-inflammatory therapies.
- Tae Won Yi
- Vikas S. Sridhar
- David Cherney